Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSD | P07339 | 4/20 | 0.43 |
| ▸ | YAP1 | P46937 | 3/20 | 0.42 |
| ▸ | REN | P00797 | 5/20 | 0.42 |
| ▸ | KLK5 | Q9Y337 | 3/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.41 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.41 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.41 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.41 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.41 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.40 |
| ▸ | PSMB8 | P28062 | 1/20 | 0.40 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.40 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.40 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.40 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.40 |
| ▸ | CTSE | P14091 | 1/20 | 0.40 |
| ▸ | PGC | P20142 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13630858 | 0.86 | ABCB1 (0.49) | CTSDCYP3A4 | |
| SCHEMBL24066642 | 0.79 | ABCB1 (0.49) | — | |
| SCHEMBL13617810 | 0.78 | SPPL2A (0.56) | — | |
| SCHEMBL13617549 | 0.77 | KLK5 (0.53) | YAP1RENKLK5PSEN1PSEN2 | |
| SCHEMBL13618023 | 0.77 | YAP1 (0.51) | YAP1RENKLK5PSMB1PSMB8 | |
| SCHEMBL24066676 | 0.77 | ABCB1 (0.50) | — | |
| SCHEMBL13617886 | 0.77 | ABCB1 (0.43) | CTSDRENKLK5PSEN1PSEN2 | |
| SCHEMBL4351993 | 0.77 | ABCB1 (0.49) | CTSD | |
| SCHEMBL4352000 | 0.77 | ABCB1 (0.49) | CTSD | |
| SCHEMBL13537940 | 0.76 | PTGES (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455497-B2 | Inhibitors of aspartyl protease | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-06-04 | — | — | US | disclosed |
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | VERTEX PHARMACEUTICALS INCORPORATED | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090274650-A1 | INHIBITORS OF ASPARTYL PROTEASE | SPINT2, DNPEP, PRSS1 | CTSD 92/4885YAP1 4559/4885REN 796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.